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A 17 year old previously healthy adolescent presented to the
emergency department with severe headache, vomiting, and an
altered state of mind. His mother reported that he had returned
home one hour before, looking confused and agitated; afterwards
hementioned a worsening headache and had vomited twice. On
arrival at the emergency department he was conscious but
drowsy and slow in answering simple questions. He reported
frontal headache (8/10 on a visual analogue scale) and
photophobia, and he was unable to stand unassisted. He was
afebrile, his heart rate was 170 beats/min, and his blood pressure
was 132/80 mm Hg. His pupils were mydriatic and poorly
reactive to light. The remainder of the physical examination
was unremarkable. He denied taking any drugs or medication,
and a urine screen test was negative for cannabinoids, opioids,
amphetamines, benzodiazepines, ethanol, and cocaine.
Computed tomography of the brain and a basic set of blood tests
were performed, and all results were normal. On further
questioning by his parents he admitted having smoked “herbal
incense” with friends in the afternoon, after which he reported
having experienced visual and auditory hallucinations.
Questions
1. Which diagnosis does this story suggest?
2. What potentially serious complications should be
considered?
3. How could you confirm the diagnosis?
4. How should this patient be managed?
Answers
1. Which diagnosis does this story suggest?
Short answer
Acute intoxication by an emerging drug of misuse, probably a
synthetic cannabinoid. Clues to the diagnosis include acute
onset, otherwise unexplained, central nervous system and
autonomic disturbances in a healthy young person with negative
drug screening tests and a history of smoking herbal incense.
Long answer
The evaluation of an adolescent or young adult presenting to
the emergency department with a change of mental status can
be challenging. The differential diagnosis is extensive,
comprising psychiatric conditions and medical conditions,
including cerebrovascular events, unreported trauma,
intoxication, carbon monoxide poisoning, epileptic disorders,
and endocrine or metabolic disorders (including inborn errors
of metabolism), as well as infectious, autoimmune, and
neoplastic diseases.1 2
Although all these possible causes should be considered, acute
intoxication by a substance of misuse should always be a strong
contender in a previously healthy adolescent presenting with
acute onset change of mental status, especially when coupled
with autonomic signs and symptoms. This possibility should
always be evaluated clinically and bymeans of a history focused
on drug consumption. Drug screening tests may detect the
presence of the most common substances of misuse, but positive
and negative results do not absolutely confirm or refute a
diagnosis, and further evaluation is needed. A positive result
does not necessarily mean that the presenting signs and
symptoms are caused by the substance detected, which could
have been taken some days before and be still present in the
urine, but not be related to the observed symptoms. However,
it may serve as an indicator of current intake of substances by
the patient, who may often take multiple drugs.3 4 By contrast,
a negative result does not rule out intoxication by other,
undetected, psychoactive substances. In this respect, particular
attention should be paid to intoxication by emerging drugs of
misuse, a vast class of chemically diverse psychoactive
substances that go largely undetected by conventional
immunoassay drug screen tests.4
“Emerging drugs of misuse” or “new psychoactive substances”
are umbrella terms for all psychoactive substances not under
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international control that pose a health threat.5 The exact number
of these drugs is unknown. In December 2013 the number of
such substances reported to the United Nations Office on Drug
and Crime reached 348, but this is probably an underestimate
because newmolecules are constantly appearing on the market.6
In the past decade, the use of these drugs has grown rapidly,
especially among adolescents and young adults, and it is a global
phenomenon.5 In the European Union almost 5% of 15-24 year
olds reported having tried a new psychoactive substance at least
once (range: 0.3% in Malta to 16.3% in Ireland),7 and even
higher figures have been reported in the United States.8
Despite often being perceived as “safe” by consumers,8 their
use is associated with a high risk of serious toxic effects, as well
as a parallel increase in emergency department visits and calls
to poison control centres.3 9 10 In addition, doctors are still
unfamiliar with these substances.11 Common classes of new
psychoactive substances include synthetic cannabinoids,
synthetic cathinones (“bath salts,” including mephedrone,
methylone, andmethylenedioxypyrovalerone), piperazines (like
benzylpiperazine), phenethylamines, tryptamines, phencyclidine
derivatives, as well as various plant derived psychoactive
substances like kratom (Mitragyna speciosa) and Salvia
divinorum. Synthetic cannabinoids and synthetic cathinones are
the most commonly encountered new psychoactive substances
in clinical practice, and possibly also the most dangerous.5
Synthetic cannabinoids, also known as “spice products,” are
designer drugs (substances developed to avoid existing drug
control measures) with very strong cannabis-like effects. They
are sold in “head shops,” in convenience stores, and on the
internet, often under catchy names like “Spice,” “K2,” “Genie,”
and “Black Mamba.” They are usually disguised as herbal
incenses, potpourris, or room aromatisers, often labelled as “not
for human consumption,” and they are commonly smoked or
ingested.
2. What potentially serious complications
should be considered?
Short answer
Synthetic cannabinoids can cause severe neurological and
psychiatric toxic effects as well as injury to other organ systems,
including myocardial infarction, cardiac dysrhythmia,
hypokalaemia, hyperthermia, and acute kidney injury. A small
number of deaths have also been reported.
Long answer
Acute intoxication by synthetic cannabinoids has been associated
with serious toxicity and even some deaths.12 Synthetic
cannabinoids act as potent agonists on cannabinoid receptors,
whereas Δ9-tetrahydrocannabinol, the major psychoactive
compound of cannabis, is only a partial agonist. This fact may
account for their greater potential for toxicity, with any misuse
easily turning into an overdose.13 Moreover, synthetic
cannabinoids also act on other neurotransmitters, which may
explain some of the differences between intoxication with
cannabis and with synthetic cannabinoids. For example,
inhibition of γ-aminobutyric acid receptors may cause anxiety,
agitation, and seizures, whereas the activation of serotonin
receptors and the inhibition of monoamine oxidases may be
responsible for hallucinations and the occurrence of serotonin
syndrome-like signs and symptoms.14 15 Furthermore, in
marketed products, synthetic cannabinoids may be deliberately
admixed with psychoactive herbs,16 or with other substances
such as β agonists like clenbuterol,17 18 opioid agonists,19 and
benzodiazepines like phenazepam,20 thus possibly creating
complex clinical presentations.
Although acute intoxication by synthetic cannabinoids has some
similarities to intoxication by high dose cannabis, it can be more
intense and associated with more prominent sympathomimetics
signs. The most commonly reported symptoms and signs are
confusion, agitation, irritability, drowsiness, tachycardia,
hypertension, diaphoresis, mydriasis, and hallucinations.21Other
neurological and psychiatric effects include seizures, suicidal
ideation, aggressive behaviour, and psychosis.22 Ischaemic stroke
has also been reported.23 Gastrointestinal toxicity may cause
xerostomia, nausea, and vomiting. Severe cardiotoxic effects
have been described, including myocardial infarction,
tachyarrhythmia, and bradyarrhythmia.24 Other potentially
serious effects include hypokalaemia, hyperglycaemia,
hyperthermia, rhabdomyolysis,25 and acute kidney injury.26 An
addiction syndrome and withdrawal symptoms have been
reported in habitual users.27
Synthetic cannabinoid intoxication should therefore be included
in the differential diagnosis of patients, most commonly
adolescents or young adults, presenting with an acute and
otherwise unexplained alteration of the central nervous system
associated with autonomic disturbances. Other situations in
which a high index of suspicion should be maintained include
atypical presentations, such as acute unexplained kidney injury
or myocardial infarction in a healthy young person.
3. How could you confirm the diagnosis?
Short answer
Synthetic cannabinoids are not usually detected by conventional
drug screening tests. In the absence of a positive history,
advanced tests like liquid chromatography-tandem mass
spectrometry may identify the substance, but these are not
generally available in the acute setting.
Long answer
The most important step is to obtain a precise history, but this
is not always possible because of the patient’s conditions or
reticence. Focused questions, such as “have you smoked or
ingested any incense, potpourri, or herbal product?,” may help
avoid unnecessary investigations and direct management.
Common street names for synthetic cannabinoids are Spice, K2,
Skunk, Incense, Bliss, Fake Weed, Yucatan Fire, Genie, Moon
Rocks, Zohai, and Black Mamba,28 whereas “bath salts” is a
common name for synthetic cathinones. It is advisable to contact
the local poison control centre, which may provide assistance
in the acute setting and set up surveillance on the distribution
of these substances. Synthetic cannabinoids, like other new
psychoactive substances, are not usually detected by
conventional drug screening tests. Advanced tests like gas
chromatography or liquid chromatography-tandem mass
spectrometry can be performed on a blood or urine specimen
at reference laboratories, but they are not generally available in
the acute setting and are used mainly for forensic investigations.
If these tests are requested, the specimen should be collected as
early as possible, preferably during the first 12 hours, because
these drugs are generally metabolised rapidly. Finally, some
synthetic cannabinoids are not detected even with advanced
testing because most laboratories have only a limited library of
reference compounds, and newermoleculesmay not be included.
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4. How should this patient be managed?
Short answer
Intoxicated patients should be observed until recovery and
should undergo further evaluations, including a battery of basic
blood tests and electrocardiography. Treatment is mainly
supportive.
Long answer
Management of acute intoxication by synthetic cannabinoids
should follow the general principles of drug misuse
emergencies.29 After stabilisation, a complete physical and
neurological examination should be performed. Patients should
be observed until recovery. Vital signs should be monitored,
including temperature, because hyperthermia is an ominous
sign that may warrant active patient cooling and expert
consultation. A battery of blood tests, including glucose,
electrolytes, creatinine, transaminases, creatine phosphokinase,
and cardiac troponin, should be requested, as well as
electrocardiography, to screen for possible complications and
toxic effects on organ systems. The simultaneous misuse of
other drugs should also be actively investigated. Drug
decontamination or enhanced elimination is not usually possible,
and there is no specific antidote. Intoxications are commonly
short lived (6-24 h), and management is mainly supportive.
Placement in a quiet, dim environment can be helpful, with
intravenous fluids as needed and long acting benzodiazepines
in case of agitation. More severe psychiatric symptoms (such
as psychotic symptoms, aggressive behaviour) may warrant a
psychiatric consultation. If antipsychotic drugs are used, the
QT interval should be monitored. A psychiatric consultation
should always be arranged in the follow-up.
Patient outcome
The patient was admitted for observation and intravenous
rehydration with normal saline. The results of a battery of blood
tests and electrocardiography were normal. He made a full
recovery in the next 12 hours. A blood specimen sent for gas
chromatography detected the presence of JWH-018 and
JWH-122, two common synthetic cannabinoids.
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